Clinical Trials Browser

Lymphatic Metastasis × Nivolumab × 90 days × Clear all

NCT03793166 2026-05-29

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

Phase 3 Active not recruiting

Carcinoma, Renal Cell, Lymphatic Metastasis